Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance - 2These Cities Led Global Jet-Setting In 2025, According To New Data
- 3The most effective method to Pick the Best Material Organization: Insider Tips
- 4Israeli lawmakers pass bill reviving death penalty for terrorists
- 5'It's doing badly': Fears grow for whale stuck off Germany's coast
- Why most Jewish Israelis back the death penalty for terrorists
- Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- What to know about the hepatitis B shot — and why Trump officials are targeting it
- ‘The White Lotus’ sparked online interest in risky anxiety pills, study says
- Sahel coups push Africa to top of global democratic declines, report finds
- Vote In favor of Your Favored Kind Of Tea
- Find the Native Culinary Customs: Local Flavors
- Beyond oil: The crucial exports blocked by Hormuz closure
- A Lone Wolf Outsmarted Hunters in the Black Forest and Then Vanished
